open access

Vol 13, No 1 (2016)
Review paper
Get Citation

Long-term schizophrenia treatment — solutions for new challenges

Agata Szulc
Psychiatria 2016;13(1):39-43.

open access

Vol 13, No 1 (2016)
Prace poglądowe - nadesłane

Abstract

Since 2002 long acting injectable (LAI) antipsychotics are available in the treatment of patients with the diagnosis of schizophrenia. Despite their efficacy and good tolerability demonstrated in numerous studies and in clinical practice, LAI antipsychotics are still under-used. Among main obstacles to its more frequent use the crucial ones are: negative or ambivalent perception of this class of medications by psychiatrists and patients anxieties connected with injection and expected pain. The results of the 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia provides evidence for the conclusion that olanzapine LAI is effective in long term maintenance treatment with good safety profile consistent with the known profile of oral olanzapine.

Abstract

Since 2002 long acting injectable (LAI) antipsychotics are available in the treatment of patients with the diagnosis of schizophrenia. Despite their efficacy and good tolerability demonstrated in numerous studies and in clinical practice, LAI antipsychotics are still under-used. Among main obstacles to its more frequent use the crucial ones are: negative or ambivalent perception of this class of medications by psychiatrists and patients anxieties connected with injection and expected pain. The results of the 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia provides evidence for the conclusion that olanzapine LAI is effective in long term maintenance treatment with good safety profile consistent with the known profile of oral olanzapine.

Get Citation

Keywords

schizophrenia, long acting injectable antipsychotics, olanzapine

About this article
Title

Long-term schizophrenia treatment — solutions for new challenges

Journal

Psychiatria (Psychiatry)

Issue

Vol 13, No 1 (2016)

Article type

Review paper

Pages

39-43

Bibliographic record

Psychiatria 2016;13(1):39-43.

Keywords

schizophrenia
long acting injectable antipsychotics
olanzapine

Authors

Agata Szulc

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl